AORT

Artivion Inc

20.11

Nov 11 • 3:22 PM ET -0.36 (-1.76%)

Healthcare Medical Devices USA Small NYSE

Peers: MDT EW LMAT ABT LIVN AVR ATRC BSX BAX TFX

| Held by: IJR VTI IWM VXF SPSM IJT IWO DFAS VTWO SLYG

Scroll to Statements

Index	RUT
Market Cap	981.17M
Enterprise Value	1.34B
Income	-17.57M
Sales	481.88M
Book/sh	9.15
Cash/sh	0.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Dec 09, 2015
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1800
IPO	Feb 12, 1993

P/E	-
Forward P/E	143.64
PEG	6.65
P/S	2.04
P/B	2.20
P/C	20.27
P/FCF	-
EV/EBITDA	26.88
EV/Sales	2.78
Quick Ratio	2.32
Current Ratio	3.72
Debt/Eq	0.91
LT Debt/Eq	0.90
Option/Short	Yes / Yes

EPS (ttm)	-0.36
EPS next Y	0.14
EPS next Q	-0.04
EPS this Y	-307.14%
EPS next Y	132.18%
EPS next 5Y	21.59%
EPS past 3/5Y	- -
Sales past 3/5Y	12.04% 11.75%
EPS Y/Y TTM	-52.01%
Sales Y/Y TTM	14.01%
EPS Q/Q	-222.00%
Sales Q/Q	9.17%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-161.01% 2.33%

Insider Own	5.33%
Insider Trans	-4.96%
Inst Own	96.78%
Inst Trans	3.79%
ROA	-1.85%
ROE	-3.97%
ROIC	-2.07%
Gross Margin	59.91%
Oper. Margin	4.91%
Profit Margin	-3.65%
SMA20	-11.52%
SMA50	-13.15%
SMA200	-29.59%
Trades

Shs Outstand	48.79M
Shs Float	46.19M
Short Float	7.39%
Short Ratio	5.03
Short Interest	3.41M
52W High	48.25 -58.32%
52W Low	19.16 4.96%
Volatility	10.34% 5.63%
ATR (14)	1.49
RSI (14)	38.36
Beta	1.29
Rel Volume	0.52
Avg Volume	678.07K
Volume	319,983

Perf Week	-23.97%
Perf Month	-5.85%
Perf Quarter	-29.22%
Perf Half Y	-9.54%
Perf YTD	-55.91%
Perf Year	-57.08%
Perf 3Y	50.86%
Perf 5Y	-3.69%
Perf 10Y	6.40%
Recom	1.00
Target Price	38.47
Prev Close	20.47
Price	20.11
Change %	-1.76%

Consensus

Strong Buy

Avg. Price Target

$38.47

Implied Upside

+91.3%

Analysts6incl. previous ratings

Rating Distribution6 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2026	Initiated	JJefferies	Buy	$31	+54.2%
Apr 10, 2026	Upgrade	LLadenburg Thalmann	Neutral → Buy	$42	+108.9%
Aug 13, 2025	Downgrade	LLadenburg Thalmann	Buy → Neutral	$38.80	+92.9%
Jun 17, 2025	Initiated	CCanaccord Genuity	Buy	$35	+74.0%
Oct 23, 2024	Initiated	JJMP Securities	Mkt Outperform	$33	+64.1%
Sep 27, 2022	Reiterated	LLake Street	Buy	$32 → $28	+39.2%
Aug 08, 2022	Initiated	LLake Street	Buy	$32	+59.1%
Mar 03, 2022	Initiated	SStifel	Buy	$30	+49.2%

Nov-05-26 06:46PM	Artivion Beats On Revenue, But A Margin Squeeze And New 2027 Perclot Headwind Drive A Steep Earnings Miss (Earnings Whispers) -20.21%
04:16PM	Artivion: Q3 Earnings Snapshot (Associated Press)
04:05PM	Artivion Reports Third Quarter 2026 Financial Results (PR Newswire)
Oct-28-26 06:19PM	Artivion Must Prove AMDS Ramp Can Offset Nexus Costs After 15% Slide (Earnings Whispers)
04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
04:10PM	Loading…
Oct-22-26 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results (PR Newswire)
Oct-20-26 11:02AM	Artivion rises as Jefferies initiates at buy, sees attractive entry point (Investing.com)
Aug-07-26 01:11AM	Artivion Inc (AORT) (Q2 2026) Earnings Call Highlights: PMA Approval and Endospan Acquisition ... (GuruFocus.com)
Aug-06-26 04:22PM	Artivion: Q2 Earnings Snapshot (Associated Press)
04:05PM	Artivion Reports Second Quarter 2026 Financial Results (PR Newswire)
Jul-28-26 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-23-26 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results (PR Newswire)
Jun-29-26 07:00AM	Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis (PR Newswire) -5.17%
Jun-10-26 04:10PM	Artivion to Participate in the 2026 Truist Securities MedTech Conference (PR Newswire)
May-18-26 11:58PM	Artivion closes Endospan buyout to acquire recently approved heart device (MedTech Dive)
12:43PM	Loading…
12:43PM	Artivion strengthens aortic arch portfolio with $135m Endospan acquisition (Medical Device Network)
07:05AM	Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS Aortic Arch System (Business Wire)
07:00AM	Artivion Completes Acquisition of Endospan Ltd. (PR Newswire)
May-07-26 05:01PM	Artivion: Q1 Earnings Snapshot (Associated Press) -28.26%
04:05PM	Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan (PR Newswire)
Apr-23-26 04:15PM	Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results (PR Newswire)
Apr-08-26 08:01PM	Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock? (Quartz)
Apr-07-26 07:00AM	Artivion Announces U.S. FDA Approval of the NEXUS Aortic Arch System (PR Newswire) +5.29%
Mar-09-26 08:31PM	Stifel Remains a Buy on Artivion (AROT) (Insider Monkey)
Mar-03-26 04:10PM	Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference (PR Newswire)
Feb-19-26 12:32AM	5 Must-Read Analyst Questions From Artivion's Q4 Earnings Call (StockStory)
Feb-13-26 11:30AM	Artivion (AORT) Stock Trades Down, Here Is Why (StockStory) -9.96%
12:32AM	AORT Q4 Deep Dive: Stent Graft and On-X Growth Offset By Tissue Flatness, Guidance Highlights Pipeline (StockStory)
12:05AM	Artivion Inc (AORT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges (GuruFocus.com)
Feb-12-26 10:10PM	Artivion Q4 Earnings Call Highlights (MarketBeat)
05:30PM	Loading…
05:30PM	Artivion (AORT) Q4 Earnings Surpass Estimates (Zacks)
04:58PM	Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations (StockStory)
04:36PM	Artivion: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Artivion Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Feb-10-26 10:08PM	What To Expect From Artivion's (AORT) Q4 Earnings (StockStory)
Feb-02-26 08:00AM	Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting (PR Newswire)
Jan-29-26 04:05PM	Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results (PR Newswire)
Jan-05-26 12:51PM	Here's Why You Should Retain Masimo Stock in Your Portfolio Now (Zacks)
Jan-01-26 11:02PM	3 Reasons to Sell AORT and 1 Stock to Buy Instead (StockStory)
Dec-30-25 10:42AM	RBOT Enters Strategic Software Partnership to Streamline Development (Zacks)
Dec-29-25 09:40AM	Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-28-25 11:35PM	1 Safe-and-Steady Stock on Our Watchlist and 2 We Avoid (StockStory)
Dec-26-25 12:20PM	EW Wins FDA Approval for SAPIEN M3 as First Transseptal TMVR Therapy (Zacks)
Dec-17-25 03:40PM	Artivion (AORT) Stock Is Up, What You Need To Know (StockStory)
12:01PM	HOLX's Genius AI Mammography Flags Missed Breast Cancer Cases (Zacks)
Dec-12-25 09:40AM	Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-11-25 10:06AM	ISRG Gets FDA Clearance to Use da Vinci SP Robot for General Surgeries (Zacks)
Dec-10-25 12:40PM	PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor (Zacks)
Nov-26-25 09:40AM	Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-25-25 10:38PM	Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q3 Teardown: Artivion (NYSE:AORT) Vs The Rest (StockStory)
Nov-13-25 12:36AM	5 Must-Read Analyst Questions From Artivion's Q3 Earnings Call (StockStory)
Nov-07-25 09:26AM	AORT Q3 Deep Dive: AMDS and On-X Outperform, Pipeline and Reimbursement Bolster Outlook (StockStory) -5.54%
12:01AM	Artivion Inc (AORT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-06-25 06:15PM	Artivion (AORT) Tops Q3 Earnings and Revenue Estimates (Zacks)
05:15PM	Artivion: Q3 Earnings Snapshot (Associated Press Finance)
04:33PM	Artivion's (NYSE:AORT) Q3 Sales Top Estimates (StockStory)
04:05PM	Artivion Reports Third Quarter 2025 Financial Results (PR Newswire)
08:00AM	Artivion Announces Treatment of First Patient with Arcevo LSA in ARTIZEN Pivotal Trial (PR Newswire)
Nov-05-25 08:50AM	Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 10:19PM	Artivion (AORT) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-29-25 04:10PM	Artivion to Participate in the Stifel 2025 Healthcare Conference (PR Newswire)
08:09AM	Strong Results and Improved Guidance Lifted Artivion (AORT) (Insider Monkey)
Oct-23-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results (PR Newswire)
Oct-15-25 11:33PM	Firing on All Cylinders: Artivion (NYSE:AORT) Q2 Earnings Lead the Way (StockStory)
12:02AM	3 Reasons to Sell AORT and 1 Stock to Buy Instead (StockStory)
Oct-13-25 08:00AM	Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE and AMDS PROTECT Trials at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting (PR Newswire)
Sep-25-25 08:48AM	Are Options Traders Betting on a Big Move in Artivion Stock? (Zacks)
Sep-05-25 04:10PM	Artivion to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference (PR Newswire)
Aug-14-25 01:35AM	5 Must-Read Analyst Questions From Artivion's Q2 Earnings Call (StockStory)
Aug-12-25 10:01AM	1 Safe-and-Steady Stock to Target This Week and 2 We Find Risky (StockStory)
Aug-11-25 09:40AM	AORT Q2 Deep Dive: Product Momentum and Pipeline Advances Drive Upgraded Guidance (StockStory)
Aug-09-25 10:05AM	Artivion price target raised to $45 from $32 at Needham (TipRanks)
Aug-08-25 12:21PM	Why Is Artivion (AORT) Stock Rocketing Higher Today (StockStory) +25.23%
04:51AM	Artivion (NYSE:AORT) Reports Strong Q2, Stock Jumps 13.1% (StockStory)
Aug-07-25 06:05PM	Artivion (AORT) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:57PM	Artivion: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Artivion Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-06-25 02:51PM	Artivion (AORT) Stock Is Up, What You Need To Know (StockStory)
Aug-05-25 11:03PM	What To Expect From Artivion's (AORT) Q2 Earnings (StockStory)
Jul-31-25 12:02AM	3 Reasons AORT is Risky and 1 Stock to Buy Instead (StockStory)
Jul-30-25 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
Jul-29-25 05:20PM	Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-24-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2025 Financial Results (PR Newswire)
Jul-23-25 12:33AM	3 Healthcare Stocks with Warning Signs (StockStory)
Jul-21-25 12:30PM	[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Jun-26-25 05:50PM	The 5 Most Interesting Analyst Questions From Artivion's Q1 Earnings Call (StockStory)
Jun-03-25 04:10PM	Artivion to Participate in Upcoming Investor Conferences (PR Newswire)
May-28-25 11:33PM	Q1 Earnings Highs And Lows: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
05:51PM	Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock (PR Newswire)
May-19-25 07:40AM	AORT Q1 Earnings Call: Early Product Launches and Supply Recovery Drive Outperformance (StockStory)
May-14-25 04:01PM	Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock (PR Newswire)
May-05-25 05:45PM	Artivion (AORT) Lags Q1 Earnings Estimates (Zacks) +15.36%
04:05PM	Artivion Reports First Quarter 2025 Financial Results (PR Newswire)
07:00AM	Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting (PR Newswire)
Apr-29-25 09:05AM	3 Stocks Under $50 That Concern Us (StockStory)
Apr-21-25 04:10PM	Artivion Announces Release Date and Teleconference Call Details for First Quarter 2025 Financial Results (PR Newswire)
Apr-15-25 05:11AM	Unpacking Q4 Earnings: Artivion (NYSE:AORT) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
Apr-10-25 09:10AM	Strength Seen in Artivion (AORT): Can Its 7.9% Jump Turn into More Strength? (Zacks)
Mar-28-25 05:04AM	Artivion (AORT): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
Mar-24-25 12:20PM	Do Options Traders Know Something About Artivion (AORT) Stock We Don't? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GREEN ANDREW M	SVP, Regulatory and Quality	Sep 10 '26	Sale	24.97	11,480	286,656	40,160	Sep 11 05:28 PM
GREEN ANDREW M	Officer	Sep 10 '26	Proposed Sale	24.97	11,480	286,657		Sep 10 11:43 AM
GREEN ANDREW M	SVP, Regulatory and Quality	Sep 02 '26	Sale	27.27	6,510	177,495	53,133	Sep 04 02:15 PM
GREEN ANDREW M	SVP, Regulatory and Quality	Sep 03 '26	Sale	26.02	1,493	38,842	51,640	Sep 04 02:15 PM
GREEN ANDREW M	Officer	Sep 03 '26	Proposed Sale	26.02	1,493	38,842		Sep 03 05:16 PM
GREEN ANDREW M	Officer	Sep 02 '26	Proposed Sale	27.27	6,510	177,498		Sep 02 04:42 PM
Stanton Marshall S.	Officer	Aug 27 '26	Proposed Sale	26.85	7,400	198,695		Aug 27 02:36 PM
Mackin James P	President & CEO	Aug 19 '26	Sale	28.95	70,000	2,026,850	877,275	Aug 20 02:11 PM
Mackin James P	Officer	Aug 19 '26	Proposed Sale	29.33	70,000	2,053,100		Aug 19 03:45 PM
GREEN ANDREW M	SVP, Regulatory and Quality	Aug 14 '26	Sale	28.55	616	17,586	59,643	Aug 17 03:18 PM
Berry Lance A	EVP, COO, CFO & Treasurer	Aug 14 '26	Sale	28.55	715	20,413	210,112	Aug 17 03:17 PM
Berry Lance A	Officer	Aug 14 '26	Proposed Sale	28.55	715	20,413		Aug 14 03:58 PM
GREEN ANDREW M	Officer	Aug 14 '26	Proposed Sale	28.55	616	17,586		Aug 14 03:17 PM
Holloway Jean F	SVP, General Counsel	Aug 12 '26	Sale	28.49	977	27,835	184,118	Aug 12 05:51 PM
GREEN ANDREW M	SVP, Regulatory and Quality	Jun 11 '26	Option Exercise	13.39	44,001	589,078	90,259	Jun 15 11:28 AM
GREEN ANDREW M	SVP, Regulatory and Quality	Jun 11 '26	Sale	20.70	44,001	910,739	60,259	Jun 15 11:28 AM
GREEN ANDREW M	Officer	Jun 11 '26	Proposed Sale	20.70	44,001	910,753		Jun 11 04:49 PM
Horton Amy	VP, Chief Accounting Officer	Mar 03 '26	Sale	37.78	901	34,036	139,088	Mar 04 06:54 PM
Holloway Jean F	SVP, General Counsel	Mar 04 '26	Sale	38.00	8,962	340,556	185,095	Mar 04 06:53 PM
Holloway Jean F	SVP, General Counsel	Mar 03 '26	Sale	37.78	3,843	145,172	194,057	Mar 04 06:53 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Mar 03 '26	Sale	37.78	2,149	81,180	60,097	Mar 04 06:51 PM
Davis John E	Chief Commercial Officer	Mar 03 '26	Sale	37.78	4,573	172,748	230,794	Mar 04 06:49 PM
Berry Lance A	EVP, COO, CFO & Treasurer	Mar 03 '26	Sale	37.78	6,316	238,591	210,827	Mar 04 06:47 PM
Mackin James P	President & CEO	Mar 03 '26	Sale	37.78	17,887	675,692	947,275	Mar 04 06:44 PM
JEAN F HOLLOWAY	Officer	Mar 04 '26	Proposed Sale	38.00	8,962	340,556		Mar 04 04:06 PM
Berry Lance A	Officer	Mar 03 '26	Proposed Sale	37.78	6,316	238,591		Mar 03 04:42 PM
Davis John E	Officer	Mar 03 '26	Proposed Sale	37.78	4,573	172,748		Mar 03 04:41 PM
Holloway Jean F	Officer	Mar 03 '26	Proposed Sale	37.78	3,843	145,172		Mar 03 04:39 PM
Stanton Marshall S.	Officer	Mar 03 '26	Proposed Sale	37.78	2,149	81,180		Mar 03 04:37 PM
Mackin James P	Officer	Mar 03 '26	Proposed Sale	37.78	17,887	675,692		Mar 03 04:19 PM
Horton Amy	Officer	Mar 03 '26	Proposed Sale	37.78	901	34,036		Mar 03 04:11 PM
Horton Amy	VP, Chief Accounting Officer	Mar 02 '26	Sale	38.02	641	24,374	132,514	Mar 03 03:25 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Mar 02 '26	Sale	38.02	1,513	57,532	40,408	Mar 03 03:04 PM
Mackin James P	President & CEO	Mar 02 '26	Sale	38.02	14,911	566,989	848,214	Mar 03 03:02 PM
Holloway Jean F	SVP, General Counsel	Mar 02 '26	Sale	38.02	2,183	83,008	170,105	Mar 03 03:00 PM
Berry Lance A	EVP, COO, CFO & Treasurer	Mar 02 '26	Sale	38.02	5,178	196,893	176,269	Mar 03 02:51 PM
Davis John E	Chief Commercial Officer	Mar 02 '26	Sale	38.02	2,784	105,861	206,522	Mar 03 02:49 PM
Holloway Jean F	Officer	Mar 02 '26	Proposed Sale	38.02	2,183	83,008		Mar 02 04:45 PM
Mackin James P	Officer	Mar 02 '26	Proposed Sale	38.02	14,911	566,989		Mar 02 04:40 PM
Davis John E	Officer	Mar 02 '26	Proposed Sale	38.02	2,784	105,861		Mar 02 04:39 PM
Horton Amy	Officer	Mar 02 '26	Proposed Sale	38.02	641	24,374		Mar 02 04:35 PM
Berry Lance A	Officer	Mar 02 '26	Proposed Sale	38.02	5,178	196,893		Mar 02 04:30 PM
Stanton Marshall S.	Officer	Mar 02 '26	Proposed Sale	38.02	1,513	57,532		Mar 02 04:28 PM
Horton Amy	VP, Chief Accounting Officer	Feb 23 '26	Sale	37.59	1,731	65,065	128,327	Feb 25 05:43 PM
Horton Amy	VP, Chief Accounting Officer	Feb 24 '26	Sale	35.69	830	29,625	127,497	Feb 25 05:43 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Feb 23 '26	Sale	37.59	2,423	91,076	43,180	Feb 25 05:36 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Feb 24 '26	Sale	35.69	1,259	44,937	41,921	Feb 25 05:36 PM
Holloway Jean F	SVP, General Counsel	Feb 23 '26	Sale	37.59	3,079	115,733	153,871	Feb 25 05:35 PM
Holloway Jean F	SVP, General Counsel	Feb 24 '26	Sale	35.69	1,668	59,536	152,203	Feb 25 05:35 PM
Mackin James P	President & CEO	Feb 23 '26	Sale	37.59	20,962	787,920	780,031	Feb 25 05:34 PM
Mackin James P	President & CEO	Feb 24 '26	Sale	35.69	13,936	497,418	766,095	Feb 25 05:34 PM
Berry Lance A	EVP, COO, CFO & Treasurer	Feb 23 '26	Sale	37.59	4,981	187,226	148,450	Feb 25 05:31 PM
Berry Lance A	EVP, COO, CFO & Treasurer	Feb 24 '26	Sale	35.69	4,485	160,083	143,965	Feb 25 05:31 PM
Davis John E	Chief Commercial Officer	Feb 23 '26	Sale	37.59	3,773	141,820	190,943	Feb 25 05:30 PM
Davis John E	Chief Commercial Officer	Feb 24 '26	Sale	35.69	2,075	74,063	188,868	Feb 25 05:30 PM
Davis John E	Officer	Feb 24 '26	Proposed Sale	35.69	2,075	74,063		Feb 24 05:05 PM
Berry Lance A	Officer	Feb 24 '26	Proposed Sale	35.69	4,485	160,083		Feb 24 04:42 PM
Holloway Jean F	Officer	Feb 24 '26	Proposed Sale	35.69	1,668	59,536		Feb 24 04:41 PM
Mackin James P	Officer	Feb 24 '26	Proposed Sale	35.69	13,936	497,416		Feb 24 04:33 PM
Stanton Marshall S.	Officer	Feb 24 '26	Proposed Sale	35.69	1,259	44,937		Feb 24 04:20 PM
Horton Amy	Officer	Feb 24 '26	Proposed Sale	35.69	830	29,625		Feb 24 04:14 PM
Horton Amy	Officer	Feb 23 '26	Proposed Sale	37.59	1,731	65,064		Feb 23 04:52 PM
Mackin James P	Officer	Feb 23 '26	Proposed Sale	37.59	20,962	787,909		Feb 23 04:48 PM
Holloway Jean F	Officer	Feb 23 '26	Proposed Sale	37.59	3,079	115,732		Feb 23 04:40 PM
Davis John E	Officer	Feb 23 '26	Proposed Sale	37.59	3,773	141,818		Feb 23 04:39 PM
Berry Lance A	Officer	Feb 23 '26	Proposed Sale	37.59	4,981	187,223		Feb 23 04:31 PM
Stanton Marshall S.	Officer	Feb 23 '26	Proposed Sale	37.59	2,423	91,075		Feb 23 04:22 PM
Davis John E	Chief Commercial Officer	Dec 15 '25	Sale	45.11	5,000	225,550	193,842	Dec 17 03:47 PM
Davis John E	Officer	Dec 15 '25	Proposed Sale	45.11	5,000	225,554		Dec 17 02:50 PM
Horton Amy	VP, Chief Accounting Officer	Dec 08 '25	Sale	44.42	4,572	203,084	130,058	Dec 09 04:59 PM
Horton Amy	Officer	Dec 08 '25	Proposed Sale	44.42	4,572	203,081		Dec 08 03:16 PM
Mackin James P	President & CEO	Dec 03 '25	Option Exercise	29.62	30,921	915,880	831,914	Dec 04 08:54 PM
Mackin James P	President & CEO	Dec 03 '25	Sale	45.46	30,921	1,405,700	800,993	Dec 04 08:54 PM
Holloway Jean F	SVP, General Counsel	Dec 03 '25	Sale	45.30	7,315	331,370	156,093	Dec 04 08:52 PM
Mackin James P	President & CEO	Dec 02 '25	Option Exercise	29.62	30,921	915,880	831,914	Dec 03 07:27 PM
Mackin James P	President & CEO	Dec 02 '25	Sale	45.56	30,921	1,408,730	800,993	Dec 03 07:27 PM
Mackin James P	Officer	Dec 03 '25	Proposed Sale	45.46	30,921	1,405,695		Dec 03 05:10 PM
JEAN F HOLLOWAY	Officer	Dec 03 '25	Proposed Sale	45.30	7,315	331,391		Dec 03 04:06 PM
Mackin James P	Officer	Dec 02 '25	Proposed Sale	46.27	30,921	1,430,715		Dec 02 10:07 AM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 21 '25	Option Exercise	14.21	47,376	672,988	71,828	Nov 24 05:23 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 21 '25	Sale	45.04	47,376	2,133,920	44,753	Nov 24 05:23 PM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 20 '25	Option Exercise	15.48	3,388	52,434	46,786	Nov 24 09:35 AM
Stanton Marshall S.	SVP, Clinical & MD Affair	Nov 20 '25	Sale	44.18	15,276	674,825	44,753	Nov 24 09:35 AM
Stanton Marshall S.	Officer	Nov 21 '25	Proposed Sale	45.04	47,376	2,133,936		Nov 21 04:34 PM
Stanton Marshall S.	Officer	Nov 20 '25	Proposed Sale	44.18	15,276	674,833		Nov 20 04:15 PM
Hoff Elizabeth A	Director	Nov 18 '25	Sale	45.10	4,200	189,412	27,189	Nov 19 01:49 PM
ELIZABETH A HOFF	Director	Nov 18 '25	Proposed Sale	45.10	4,200	189,413		Nov 18 04:05 PM
Holloway Jean F	SVP, General Counsel	Nov 17 '25	Option Exercise	29.62	6,394	189,390	169,802	Nov 18 01:11 PM
Holloway Jean F	SVP, General Counsel	Nov 14 '25	Option Exercise	29.62	6,393	189,361	169,801	Nov 18 01:11 PM
Holloway Jean F	SVP, General Counsel	Nov 17 '25	Sale	45.17	6,394	288,817	163,408	Nov 18 01:11 PM
Holloway Jean F	SVP, General Counsel	Nov 14 '25	Sale	45.00	6,393	287,685	163,408	Nov 18 01:11 PM
Davis John E	Chief Commercial Officer	Nov 17 '25	Option Exercise	29.62	6,394	189,390	205,236	Nov 18 01:03 PM
Davis John E	Chief Commercial Officer	Nov 14 '25	Option Exercise	29.62	6,393	189,361	205,235	Nov 18 01:03 PM
Davis John E	Chief Commercial Officer	Nov 17 '25	Sale	45.17	6,394	288,817	198,842	Nov 18 01:03 PM
Davis John E	Chief Commercial Officer	Nov 14 '25	Sale	44.67	6,393	285,575	198,842	Nov 18 01:03 PM
Horton Amy	VP, Chief Accounting Officer	Nov 17 '25	Sale	45.73	6,000	274,380	135,380	Nov 18 12:57 PM
Davis John E	Officer	Nov 17 '25	Proposed Sale	45.17	6,394	288,817		Nov 17 12:36 PM
Horton Amy	Officer	Nov 17 '25	Proposed Sale	45.73	6,000	274,382		Nov 17 12:23 PM
Holloway Jean F	Officer	Nov 17 '25	Proposed Sale	45.17	6,394	288,817		Nov 17 12:04 PM
Holloway Jean F	Officer	Nov 14 '25	Proposed Sale	45.00	6,393	287,685		Nov 14 02:51 PM

Artivion, Inc. engages in the manufacture, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes aortic stents and stent grafts, surgical sealants, and On-X products. The Preservation Services segment offers cardiac and vascular tissue preservation services. The company was founded on January 19, 1984, and is headquartered in Kennesaw, GA.

ChairmanMr. James Patrick Mackin

EVPMr. Lance A. Berry CPA

Senior VPMs. Jean F. Holloway Esq.

Senior VP & Chief Commercial OfficerMr. John E. Davis

VP & Chief Accounting OfficerMs. Amy D. Horton CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

AORT

Artivion Inc

Upgrade your Finviz experience

All the Features.
Half the Price.